These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 19995331)

  • 21. An insight into the interaction between clopidogrel and proton pump inhibitors.
    Shah BS; Parmar SA; Mahajan S; Mehta AA
    Curr Drug Metab; 2012 Feb; 13(2):225-35. PubMed ID: 22300021
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation: a retrospective cohort study].
    Yasu T; Ikee R; Miyasaka Y; Chubachi H; Saito S
    Yakugaku Zasshi; 2010 Dec; 130(12):1743-50. PubMed ID: 21139402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clopidogrel, CYP2C19, and a Black Box.
    Ford NF; Taubert D
    J Clin Pharmacol; 2013 Mar; 53(3):241-8. PubMed ID: 23381692
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clopidogrel pharmacogenomics and risk of inadequate platelet inhibition: US FDA recommendations.
    Ellis KJ; Stouffer GA; McLeod HL; Lee CR
    Pharmacogenomics; 2009 Nov; 10(11):1799-817. PubMed ID: 19891556
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clopidogrel pharmacogenetics: metabolism and drug interactions.
    Close SL
    Drug Metabol Drug Interact; 2011; 26(2):45-51. PubMed ID: 21819266
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clopidogrel and proton pump inhibitors--where do we stand in 2012?
    Drepper MD; Spahr L; Frossard JL
    World J Gastroenterol; 2012 May; 18(18):2161-71. PubMed ID: 22611308
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proton-pump inhibitors in patients requiring antiplatelet therapy: new FDA labeling.
    Johnson DA; Chilton R; Liker HR
    Postgrad Med; 2014 May; 126(3):239-45. PubMed ID: 24918808
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Proton pump inhibitors and clopidogrel.
    Gaglia MA; Waksman R
    Cardiovasc Ther; 2010 Jun; 28(3):169-76. PubMed ID: 20345494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differential inhibitory effects of proton pump inhibitors on the metabolism and antiplatelet activities of clopidogrel and prasugrel.
    Chen CH; Yang JC; Uang YS; Lin CJ
    Biopharm Drug Dispos; 2012 Jul; 33(5):278-83. PubMed ID: 22623337
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of human cytochrome P450 inhibition by the thienopyridines prasugrel, clopidogrel, and ticlopidine.
    Hagihara K; Nishiya Y; Kurihara A; Kazui M; Farid NA; Ikeda T
    Drug Metab Pharmacokinet; 2008; 23(6):412-20. PubMed ID: 19122335
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CYP2C19 genetic polymorphism, rabeprazole and esomeprazole have no effect on the antiplatelet action of clopidogrel.
    El-Halabi MM; Zgheib N; Mansour NM; Malli A; Ghaith OA; Mahfouz R; Alam S; Sharara AI
    J Cardiovasc Pharmacol; 2013 Jul; 62(1):41-9. PubMed ID: 23474843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel.
    Nishiya Y; Hagihara K; Kurihara A; Okudaira N; Farid NA; Okazaki O; Ikeda T
    Xenobiotica; 2009 Nov; 39(11):836-43. PubMed ID: 19845434
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies.
    Angiolillo DJ; Gibson CM; Cheng S; Ollier C; Nicolas O; Bergougnan L; Perrin L; LaCreta FP; Hurbin F; Dubar M
    Clin Pharmacol Ther; 2011 Jan; 89(1):65-74. PubMed ID: 20844485
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response.
    Gong IY; Crown N; Suen CM; Schwarz UI; Dresser GK; Knauer MJ; Sugiyama D; DeGorter MK; Woolsey S; Tirona RG; Kim RB
    Eur Heart J; 2012 Nov; 33(22):2856-2464a. PubMed ID: 22374717
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinically relevant interaction between clopidogrel and proton pump inhibitors].
    Alban S; Dingermann T; Griese N; Kämmerer W; Schubert-Zsilavecz M; Schulz M; Trenk D; Zagermann-Muncke P
    Pharm Unserer Zeit; 2009; 38(4):370-1. PubMed ID: 19572357
    [No Abstract]   [Full Text] [Related]  

  • 36. In brief: Clopidogrel and omeprazole.
    Med Lett Drugs Ther; 2010 Nov; 52(1352):93. PubMed ID: 21166090
    [No Abstract]   [Full Text] [Related]  

  • 37. Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.
    Tsantes AE; Ikonomidis I; Papadakis I; Bonovas S; Gialeraki A; Kottaridi C; Kyriakou E; Kokori S; Douramani P; Kopterides P; Karakitsos P; Lekakis J; Kapsimali V
    Thromb Res; 2013 Aug; 132(2):e105-11. PubMed ID: 23830212
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Factors associated with clopidogrel nonresponsiveness.
    Momary KM; Dorsch MP
    Future Cardiol; 2010 Mar; 6(2):195-210. PubMed ID: 20230261
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel.
    Ogilvie BW; Yerino P; Kazmi F; Buckley DB; Rostami-Hodjegan A; Paris BL; Toren P; Parkinson A
    Drug Metab Dispos; 2011 Nov; 39(11):2020-33. PubMed ID: 21795468
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of drug interactions on biotransformation and antiplatelet effect of clopidogrel in vitro.
    Zahno A; Brecht K; Bodmer M; Bur D; Tsakiris DA; Krähenbühl S
    Br J Pharmacol; 2010 Sep; 161(2):393-404. PubMed ID: 20735423
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.